Letter from the Editor
Dear JITC Readers:
Happy New Year! With the new year comes a number of new and exciting developments for the Journal for ImmunoTherapy of Cancer (JITC).
JITC is pleased to announce its transition to a Continuous Article Publishing (CAP) model as of January 2018. Under the CAP model, all accepted articles are published immediately upon final production clearance, rather than scheduled for a future publication date/issue. This guarantees faster times to publication for all articles, ensuring new research is accessible and citable faster than ever before.
JITC will also be receiving its first Impact Factor in the 2018 Journal Citation Reports (JCR), due to publish this summer. In addition to all new articles being published in a journal with an impact factor, all authors who previously published in JITC will have their prior publications tied to this prestigious journal metric. My sincerest appreciation goes out to the many editors, reviewers, and authors who have contributed to JITC’s success over the past few years, bringing the journal to this important milestone.
In addition to expanded outreach for all published articles, JITC is providing a limited-time offer of additional promotional coverage for papers published in the three upcoming series: Emerging Immunotherapeutic Agents, New Regulatory Approvals in Cancer Immunotherapy, and Challenges in Clinical Management. Coverage includes dedicated series emails to SITC’s database of over 24,000 cancer immunotherapy professionals, social media promotion, an announcement on SITC CONNECT, and more. Submission guidelines and content scopes for these thematic series are now available with submissions welcome through Friday, March 2, 2018.
With best regards,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer